Abstract:BACKGROUND: It is not known whether premenopausal women who report low sexual satisfaction and have low circulating testosterone levels will benefit from testosterone therapy.OBJECTIVE: To evaluate the effects of exogenous testosterone in premenopausal women reporting diminished sexual function.DESIGN: Randomized, double-blind, placebo-controlled, dose-ranging trial.SETTING: 6 Australian medical centers.PATIENTS: 261 women age 35 to 46 years who reported a decrease in satisfying sexual activity relative to their younger years and had a morning serum free testosterone level less than 3.8 pmol/L (<1.1 pg/mL).INTERVENTION: 3 different doses of testosterone administered by a metered-dose transdermal spray for 16 weeks or placebo.MEASUREMENTS: The primary outcome was the mean number of self-reported satisfactory sexual events (SSEs) over 28 days at week 16. The frequency of SSEs, total number of sexual events (every 4 weeks), scores from the modified Sabbatsberg Sexual Self-Rating Scale and the Psychological General Well-Being Index, and safety variables were also measured.RESULTS: The number of SSEs increased during the treatment period in the active treatment groups and the placebo group. The mean number of SSEs over 28 days at week 16 was statistically significantly greater for women treated with the intermediate dose of testosterone therapy (one 90-microL spray) than for women treated with placebo. The least-squares mean was 2.48 versus 1.70 SSEs, respectively (event rate ratio, 1.49 [95% CI, 1.01 to 2.18]; P = 0.04). The frequency of SSEs in women treated with low and high doses of testosterone did not differ from that in women who took placebo. The rate ratios based on the least-squares mean rates of SSEs during weeks 4 to 16 for each treatment group showed statistically significant or borderline significant increases in all testosterone groups compared with the placebo group. The rate ratios for the one 56-microL spray, one 90-microL spray, and two 90-microL sprays treatment groups were 1.34 (CI, 0.97 to 1.85; P = 0.081), 1.48 (CI, 1.07 to 2.06; P = 0.018), and 1.38 (CI, 1.00 to 1.92; P = 0.052), respectively. At week 16, 95% of women treated with the one 90-microL dose had a free testosterone level less than the upper limit of the reference range for women. The most frequently reported adverse event was hypertrichosis, which was dose-related and mostly confined to the application site. No clinically relevant changes in blood test values, serum biochemical variables, or vital signs occurred.LIMITATION: The study duration was short, and the placebo effect was strong.CONCLUSION: A daily 90-microL dose of transdermal testosterone improves self-reported sexual satisfaction for premenopausal women with reduced libido and low serum-free testosterone levels by a mean of 0.8 SSE per month. The rate of SSEs with higher and lower testosterone doses did not differ from that with placebo.

Effect of Injection of Testosterone Undecanoate and Depot Medroxyprogesterone Acetate on the Suppression of Spermatogenesis

Male Hormonal Contraception: Effects of Injections of Testosterone Undecanoate and Depot Medroxyprogesterone Acetate at Eight-Week Intervals in Chinese Men

Comparison of Testosterone Undecanoate (TU) and Testosterone Enanthate (TE) with Combination of Depot Medroxyprogesterone Acetate (DMPA) on Spermatogenic Cells in Men

DDDT_A_270519 3673..3682

Recovery of Male Reproductive Function After Ceasing Prolonged Testosterone Undecanoate Injections.

Effectiveness of Testosterone Undecanoate Treatment in Men with Asthenospermia

Efficacy of Combined Testosterone Undecanoate with Tamoxifen Citratein Treatment for Spermatogenic Arrest

Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment with Monthly Depot Formulation of Domestic Substitute of Leuprorelin Acetate Microspheres for Metastatic Prostate Cancer

Efficacy and Safety of Degarelix in Patients with Prostate Cancer: Results from a Phase III Study in China

A study on the effect of using different dosage of DMPA on bone metabolism

Clinical observation of Compound Xuanju Capsule combined with Testosterone Undecanoate Capsule in treatment of oligoasthenospermia

Effects of Low-Dose Testosterone Undecanoate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Male Osteoporosis with Low Serum Testosterone.

Application of Depot Medroxyprogesterone Acetate in Breast-Feeding Women

Comparison of clinical effects of the high depot of goserelin acetate with the conventional depot in patients with advanced prostate cancer

Self-control Study on Reduced-Dose Depot Versus Daily Administration of Gonadotrophin-Releasing Hormone Agonists for Pituitary Desensitization in in Vitro Fertilization Cycles.

Clinical study of a small dose of androgen for the treatment of oligo-asthenospermatism

Clinical Outcomes of Using Three Gonadatropins and Medroxyprogestrone Acetate (MPA) During Ovarian Stimulation in Normal Ovulatory Women Undergoing IVF/ICSI Treatments

A dose-response and meta-analysis of dehydroepiandrosterone (DHEA) supplementation on testosterone levels: perinatal prediction of randomized clinical trials

The Study on the Effect of Using Depo Medroxyprogesterone Acetate for Contraception on Bone Metabolism

Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal Women

Comparison of Patterns of Use and Clinical Outcomes Between Injections of Testosterone Undecanoate and Testosterone Cypionate: An Electronic Health Record Cohort Study